Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
- PMID: 29525051
- DOI: 10.1016/j.jad.2018.02.025
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Abstract
Background: The dissociative anesthetic agent ketamine is increasingly being utilized to treat depression, despite not having FDA (Food and Drug Administration) approval for this indication. There are many questions about the potential risks of this treatment and hence the proper setting and degree of monitoring required to ensure patient safety. There is limited data about the cardiovascular safety of ketamine when administered at subanesthetic doses to treat depression.
Methods: 66 patients in the Department of Psychiatry at Emory University received a total of 684 ketamine infusions between 2014 and 2016. Ketamine was dosed at 0.5 mg/kg body weight and infused over 40 min. Blood pressure was measured every 10 min during the infusions and every 15 min thereafter.
Results: Mean age of the patients was 56.7 years, 87.9% had unipolar depression and 36.1% had essential hypertension. No infusions were discontinued due to instability of vital signs, adverse physiological consequences or acute psychotomimetic effects. The biggest increases in blood pressure were measured at 30 min (systolic 3.28 mmHg, diastolic 3.17 mmHg). Hypertensive patients had higher blood pressure peaks during the infusions. Blood pressures returned to baseline during post-infusion monitoring. There was no development of tolerance to the blood pressure elevating effects of ketamine between the first and sixth infusions.
Limitations: This is a single site, retrospective analysis, of patients who were spontaneously seeking clinical care.
Conclusions: The blood pressure changes observed when ketamine is administered over 40 min at 0.5 mg/kg for the treatment of depression are small, well tolerated and clinically insignificant.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.J Psychopharmacol. 2021 Feb;35(2):159-167. doi: 10.1177/0269881120936909. Epub 2020 Jul 28. J Psychopharmacol. 2021. PMID: 32720857 Clinical Trial.
-
Blood pressure changes during ketamine infusion for the treatment of depression.Gen Hosp Psychiatry. 2024 Sep-Oct;90:62-67. doi: 10.1016/j.genhosppsych.2024.07.001. Epub 2024 Jul 4. Gen Hosp Psychiatry. 2024. PMID: 38991311
-
Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.J Clin Psychiatry. 2017 Apr;78(4):e415-e419. doi: 10.4088/JCP.17f11567. J Clin Psychiatry. 2017. PMID: 28448702 Review.
-
Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.World J Biol Psychiatry. 2016 Apr;17(3):230-8. doi: 10.3109/15622975.2016.1142607. Epub 2016 Feb 26. World J Biol Psychiatry. 2016. PMID: 26919405 Free PMC article. Clinical Trial.
-
Side-effects associated with ketamine use in depression: a systematic review.Lancet Psychiatry. 2018 Jan;5(1):65-78. doi: 10.1016/S2215-0366(17)30272-9. Epub 2017 Jul 27. Lancet Psychiatry. 2018. PMID: 28757132
Cited by
-
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.CNS Drugs. 2021 Aug;35(8):881-892. doi: 10.1007/s40263-021-00837-6. Epub 2021 Jul 20. CNS Drugs. 2021. PMID: 34283390 Free PMC article.
-
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.CNS Drugs. 2020 Mar;34(3):299-310. doi: 10.1007/s40263-020-00699-4. CNS Drugs. 2020. PMID: 31994024 Free PMC article.
-
Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.Front Psychiatry. 2022 Sep 29;13:1017504. doi: 10.3389/fpsyt.2022.1017504. eCollection 2022. Front Psychiatry. 2022. PMID: 36245888 Free PMC article.
-
Ketamine: A Review for Clinicians.Focus (Am Psychiatr Publ). 2018 Jul;16(3):243-250. doi: 10.1176/appi.focus.20180012. Epub 2018 Jul 16. Focus (Am Psychiatr Publ). 2018. PMID: 31975918 Free PMC article. Review.
-
Noncardiac Chest Pain and Hypertensive Urgency During Long-term Intravenous Racemic Ketamine for Treatment-Resistant Depression.J Clin Psychopharmacol. 2025 Jan-Feb 01;45(1):49-52. doi: 10.1097/JCP.0000000000001939. Epub 2024 Nov 18. J Clin Psychopharmacol. 2025. PMID: 39714790 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical